Multiple endocrine neoplasia type 2 and glial cell line-derived neurotrophic factor

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 2, 1997, Pages 130-137

  Learoyd, Diana L ^a   Capes, Amanda G ^a   Robinson, Bruce G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013596764     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199704000-00009     Document Type: Article

References (91)

1. Eng C, Clayton D, Schuffenecker I, Lenoir GM, Cote GJ, Gagel RF, Ploos van Amstel H, Lips CJM, Nishisho I, Takai S-I, et al.: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996, 276:1575-1579. The largest and most recent analysis of genotype-phenotype correlations in MEN 2. It includes information that will guide clinical decision making.
2. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA: Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995, 118:936-942.
3. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papl L, et al.: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-460.
4. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-856.
5. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Niederle B, et al. for the International RET Mutation Consortium: Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238:343-346.
6. Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, ret by DNA rearrangement. Cell 1985, 42:581-588.
7. Pasini B, Hofstra RM, Yin L, Bocciardi R, Santamaria G, Grootscholten PM, Ceccherini I, Patrone G, Priolo M, Buys CH, Romeo G: The physical map of the human RET proto-oncogene. Oncogene 1995, 11:1737-1743.
8. Myers SM, Eng C, Ponder BAJ, Mulligan LM: Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995, 11:2039-2045.
9. Lorenzo MJ, Eng C, Mulligan LM, Stonehouse TJ, Healey CS, Ponder BAJ, Smith DP: Multiple mRNA isoforms of the human RET proto-oncogene generated by alternate splicing. Oncogene 1995, 10:1377-1383.
10. Bunone G, Borrello MG, Picetti R, Bongarzone I, Peverali FA, de Francisas V, Delia Valle G, Pierotti MA: Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. Exp Cell Res 1995, 217:92-99.
11. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H: Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988, 3:571-578.
12. Takahashi M, Buma Y, Hiai H: Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 1989, 4:805-806.
13. Santoco M, Wong WT, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A, Di Fiore PP: An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Mol Cell Biol 1994, 14:663-675.
14. Santoro M, Carlomagno F, Romano A, Boltaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267:381-383. This paper demonstrates dimerization of RET in the presence of MEN 2 mutations with consequent activation of RET tyrosine kinase activity. The codon 918 mutation is also shown to alter the substrate specificity of the RET tyrosine kinase.
15. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, et al.: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 1996, 16:2151-2163.
16. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti MG, Pelicci PG, Pierotti MA: The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene 1994, 9:1661-1668.
17. Pandey A, Liu X, Dixon JE, Di Fiore PP, Dixit VM: Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. J Biol Chem 1996, 271:10607-10610.
18. Durick K, Yao VJ, Borrello MG, Bongarzone I, Pierotti MA, Taylor SS: Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2. J Biol Chem 1995, 270:24642-24645.
19. Carson EB, McMahon M, Baylin SB, Nelkin BD: Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res 1995, 55:2048-2052.
20. Asai N, Iwashita T, Matsuyama M, Takahashi M: Mechanism of activation of the rat proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995, 15:1613-1619. This study demonstrates ligand-independent dimerization of RET in the presence of the MEN 2A mutations.
21. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994, 91:1579-1583.
22. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ: Point mutation within the tyrosine kinase domain of the RET protooncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 1994, 3:237-241.
23. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T. Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, et al.: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-376.
24. Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, et al.: Catalytic specificity of protein tyrosine kinases is critical for selective signalling. Nature 1995, 373:536-539. This paper demonstrates that the codon 918 mutation alters the specificity of the RET tyrosine kinase for various substrates.
25. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, et al.: RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995, 11:2419-2427.
26. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
27. Williams GH, Rooney S, Thomas GA, Cummins G, Williams ED: Ret activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br J Cancer 1996, 74:585-589.
28. Ito T, Seyama T, Iwamoto KS, Mizuno T, Tronko ND, Komissarenko IV, Cherstovoy ED, Satow Y, Takeichi N, Dohi K, Akiyama M: Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 1994, 344:259.
29. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fekete C, Ponder BAJ, Munnich A: Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:378-380.
30. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Lerone M, Kaariainen H, Martucciello G: Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:377-378.
31. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V: Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994, 367:380-383.
32. Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE: Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 1996, 271:5309-5312.
33. Frank Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, et al. for the German Medullary Thyroid Carcinoma Study Group: Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 1996, 81:1780-1783.
34. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, et al.: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. Nat Genet 1994, 6:70-74.
35. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM: RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994, 3:1939-1943.
36. Peacock ML, Borst MJ, Sweet JD, Decker RA: Detection of RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis. Hum Mutat 1996, 7:100-104.
37. Marsh DJ, Robinson BG, Andrew S, Richardson A-L, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ: A rapid screening method for mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma families. Genomics 1994, 23:477-479.
38. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton Bligh P, Robinson BG: The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 1996, 44:213-220.
39. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al.: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828-835.
40. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G: Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995, 80:3088-3090. This is the first large series in which the poor prognosis associated with the presence of a somatic codon 918 mutation was demonstrated. This was supported by subsequent data from Romei et al. (J Clin Endocrinol Metab 1996, 81:1619-1622).
41. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G: Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995, 80:3088-3090. This is the first large series in which the poor prognosis associated with the presence of a somatic codon 918 mutation was demonstrated. This was supported by subsequent data from Romei et al. (J Clin Endocrinol Metab 1996, 81:1619-1622).
42. Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG: Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996, 56:1241-1243. This study demonstrated somatic mutations in addition to germline mutations in hereditary MTCs. This was the first example of Knudson's two-hit hypothesis (Proc Natl Acad Sci U S A 1971, 68:820-823) being described in an oncogene.
43. Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG: Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996, 56:1241-1243. This study demonstrated somatic mutations in addition to germline mutations in hereditary MTCs. This was the first example of Knudson's two-hit hypothesis (Proc Natl Acad Sci U S A 1971, 68:820-823) being described in an oncogene.
44. Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971, 68:820-823.
45. Landsvater RM, de Wit MJ, Zewald RA, Hofstra RMW, Buys CHCM, van Amstel HKP, Hoppener JWM, Lips CJM: Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res 1996, 56:853-855.
46. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA: Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996, 56:2167-2170.
47. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Pfragner R, Behmel A, Lorenzo MJ, et al.: Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosom Cancer 1995, 12:209-212.
48. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C: Somatic and MEN2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 1994, 3:1259-1262.
49. Marsh DJ, Learoyd DL, Andrew SD, Krishnan U, Pojer R, Richardson A-L, Delbridge L, Eng C, Robinson BG: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 1996, 44:249-251.
50. Blaugrund JE, Johns MM, Eby YJ, Ball DW, Baylin SB, Hruban RH, Sidransky D: RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994, 3:1895-1897.
51. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F: Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996, 81:1619-1622.
52. Marsh DJ, Andrew SD, Learoyd DL, Pojer R, Eng C, Robinson BG: Deletion-insertion encompassing RET codon 634 is associated with medullary thyroid carcinoma. Hum Mutat 1997, in press.
53. Jhiang SM, Fithian L, Weghorst CM, Clark OH, Falko JM, Odorisio TM, Mazzaferri EL: Ret mutation screening in men2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 1996, 6:115-121.
54. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA: A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10:509-513.
55. Hofstra RMW, Stelwagen T, Stulp RP, Dejong D, Hulsbeek M, Kamsteeg EJ, Vandenberg A, Landsvater RM, Vermey A, Molenaar WM, et al.: Extensive mutation scanning of ret in sporadic medullary thyroid carcinoma and of ret and vhl in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 1996, 81:2881-2884.
56. Wohllk N, Cote GJ, Bugalho MMJ, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF: Relevance of ret proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81:3740-3745.
57. Komminoth P, Roth J, Mulettafeurer S, Sareaslani P, Seelentag WKF, Heitz PU: Ret proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996, 81:2041-2046.
58. Lindor NM, Honchel R, Khosla S, Thibodeau SN: Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 1995, 80:627-629.
59. Beldjord C, Desclaux Arramond F, Raffin Sanson M, Corvol JC, De Keyzer Y, Luton JP, Ptouin PF, Bertagna X: The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 1995, 80:2063-2068.
60. Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN: Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1996, 81:2711-2718.
61. Padberg BC, Schroder S, Jochum W, Kastendieck H, Roth J, Heitz PU, Komminoth P: Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol 1995, 147:1600-1607.
62. Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, et al.: Primary hyperparathyroidism in multiple endocrine neoplasia type Na: retrospective French multicentric study. World J Surg 1996, 20:808-813.
63. Jing S, Wen D, Yu Y, Hoist PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, et al.: GDNF-induced activation of the RET protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 1996, 85:1113-1124. One of the first studies to identify GDNF as a ligand for RET. A new protein, GDNFR-α, was also identified as a component of the ligand-receptor interaction.
64. Treanor JJS, Goodman L, de Sauvage F, Stone DM, Poulosn KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, et al.: Characterization of a multicomponent receptor for GDNF. Nature 1996, 382:80-83. One of the first studies to identify GDNF as a ligand for RET. A new protein, GDNFR-α, was also identified as a component of the ligand-receptor interaction.
65. Trupp M, Arenas E, Fainzilber M, Nilsson A-S, Sieber B-A, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U, et al.: Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996, 381:785-793. One of the first studies to identify GDNF as a ligand for RET.
66. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
67. Schindelhauer D, Schuffenhauer S, Gasser T, Steinkasserer A, Meitinger T: The gene coding for glial cell line derived neurotrophic factor (GDNF) maps to chromosome 5p12-p13.1. Genomics 1995, 28:605-607.
68. Springer JE, Seeburger JL, He J, Gabrea A, Blankenhorn EP, Bergman LW: cDNA sequence and differential mRNA regulation of two forms of glial cell line-derived neurotrophic factor in Schwann cells and rat skeletal muscle. Exp Neurol 1995, 131:47-52.
69. Mount HT, Dean DO, Alberch J, Dreyfus CF, Black IB: Glial cell line-derived neurotrophic factor promotes the survival and morphologic differentiation of Purkinje cells. Proc Natl Acad Sci U S A 1995, 92:9092-9096.
70. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, Koliatsos VE, Rosenthal A: GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994, 266:1062-1064.
71. Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E, Ibanez CF: Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell Biol 1995, 130:137-148.
72. Sanchez MP, Silos Santiago I, Frisen J, He B, Lira SA, Barbacid M: Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996, 382:70-73. Describes the effects of mutation or deletion of the GDNF gene in mice, high-lighting the phenotypic similarities to the ret-deficient mouse (see Schuchardt et al., Nature 1994, 367:380-383).
73. Sanchez MP, Silos Santiago I, Frisen J, He B, Lira SA, Barbacid M: Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996, 382:70-73. Describes the effects of mutation or deletion of the GDNF gene in mice, high-lighting the phenotypic similarities to the ret-deficient mouse (see Schuchardt et al., Nature 1994, 367:380-383).
74. Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, et al.: Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996, 382:73-76. Describes the effects of mutation or deletion of the GDNF gene in mice, high-lighting the phenotypic similarities to the ret-deficient mouse (see Schuchardt et al., Nature 1994, 367:380-383).
75. Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, et al.: Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996, 382:73-76. Describes the effects of mutation or deletion of the GDNF gene in mice, high-lighting the phenotypic similarities to the ret-deficient mouse (see Schuchardt et al., Nature 1994, 367:380-383).
76. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver Moore K, Rosenthal A: Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996, 382:76-79. Describes the effects of mutation or deletion of the GDNF gene in mice, high-lighting the phenotypic similarities to the ret-deficient mouse (see Schuchardt et al., Nature 1994, 367:380-383).
77. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver Moore K, Rosenthal A: Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996, 382:76-79. Describes the effects of mutation or deletion of the GDNF gene in mice, high-lighting the phenotypic similarities to the ret-deficient mouse (see Schuchardt et al., Nature 1994, 367:380-383).
78. Pachnis V, Mankoo B, Costantini F: Expression of the c-ret proto-onco-gene during mouse embryogenesis. Development 1993, 119:1005-1017.
79. Hellmich HL, Kos L, Cho ES, Mahon KA, Zimmer A: Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelial-mesenchymal interactions. Mech Dev 1996, 54:95-105.
80. Worby CA, Vega OC, Zhao Y, Chao HH-J, Seasholtz AF, Dixon JE: Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 1996, 271:619-622. Previous studies of second-messenger systems linked to RET activation have utilized chimeric receptors. This study was the first to examine these systems using the recently identified RET ligand GDNF.
81. Vega QC, Worby CA, Lechner MS, Dixon JE, Dressier GR: Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis. Proc Natl Acad Sci U S A 1996, 93:10657-10661.
82. Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A: Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat Genet 1996, 14:341-344.
83. Salomon R, Attie T, Pelet A, Bidaud C, Eng C, Amiel J, Sarnacki S, Goulet O, Ricour C, Nihoul-Fekete C, et al.: Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease. Nat Genet 1996, 14:345-347.
84. Gagel RF, Cote GJ, Martins Bugalho MJ, Boyd AE, Cummings T, Goepfert H, Evans DB, Cangir A, Khorana S, Schultz PN: Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995, 238:333-341.
85. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr: Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996, 31:177-181.
86. Frilling A, Dralle H, Eng C, Raue F, Broelsch CE: Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995, 118:1099-1103.
87. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F, Iacconi P, Basolo F, Martino E, Pinchera A: Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 1995, 118:1031-1035.
88. Okamoto T, Obara T, Ito Y, Yamashita T, Kanbe M, Iihara M, Hirose K, Yamazaki K: Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A. Endocr J 1996, 43:169-175.
89. Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, et al. for the Euromen Study Group: Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Intern Med 1995, 238:363-367.
90. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML: Prophylactic surgery for multiple endocrine neoplasia type iia after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 1996, 20:814-821.
91. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T: Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996, 6:305-310.